false
0001235912
0001235912
2024-01-03
2024-01-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 3, 2024
CVRx,
Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40545 |
|
41-1983744 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
9201
West Broadway Avenue, Suite 650
Minneapolis,
MN 55445
(Address of principal executive offices) (Zip
Code)
(763)
416-2840
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
stock, par value $0.01 per share |
|
CVRX |
|
The Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On January 8, 2024, CVRx, Inc. (the
“Company”) issued a press release announcing certain preliminary financial results for
the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 and
is incorporated herein by reference.
The information contained in this Item 2.02,
including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section and is not incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 8, 2024, the Company announced
that its President and Chief Executive Officer, Nadim Yared, provided notice to the Company’s Board of Directors (the “Board”)
of his plans to retire upon the completion of a deliberate succession process and the appointment of a successor. Both Mr. Yared
and the Board are committed to a planful and deliberate process to identify his successor, and Mr. Yared will remain in his current
role until a new Chief Executive Officer is appointed. The Board is currently conducting a search to identify a new Chief Executive Officer
with the assistance of a leading executive search firm.
Item 8.01. Other Events.
As disclosed above, on January 8, 2024,
the Company issued a press release announcing preliminary financial results for the fourth quarter and fiscal year ended December 31,
2023.
Fourth Quarter 2023
Total revenue for the fourth quarter of 2023
is expected to be in the range of approximately $11.2 million to $11.3 million, representing an increase of approximately 56% to 58% over
fourth quarter 2022 revenue of $7.2 million. Total revenue generated in the fourth quarter of 2023 is expected to be comprised of approximately
$10.2 million in U.S. heart failure revenue, $1.0 million in European revenue and $0.1 million in U.S. legacy revenue.
Full Year 2023
Total revenue for full year 2023 is expected
to be in the range of approximately $39.2 million to $39.3 million, representing an increase of approximately 74% to 75% over full year
2022 revenue of $22.5 million. Total revenue generated in 2023 is expected to be comprised of approximately $34.6 million in U.S. heart
failure revenue, $4.2 million in European revenue and $0.5 million in U.S. legacy revenue.
As of December 31, 2023, the Company
had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023. The number of sales territories in the
U.S. increased by three to a total of 38 during the three months ended December 31, 2023.
As of December 31, 2023, cash and cash equivalents were $91 million.
The foregoing estimated financial results for the fourth quarter and
full year 2023 are preliminary, unaudited and represent the most recent current information available to Company management. The
Company’s actual results may differ from these estimated financial results, including due to the completion of its financial
closing procedures and final adjustments. The Company expects to issue full financial results for the fourth quarter and full year 2023
in late January 2024.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CVRx, Inc. |
|
|
Date: January 8, 2024 |
By: |
/s/ Jared Oasheim |
|
|
Name: Jared Oasheim |
|
|
Its: Chief Financial Officer |
Exhibit 99.1
CVRx Reports
Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
| · | Fourth
quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56%
to 58% |
| · | Full
year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to
75% |
| · | President
and CEO Nadim Yared plans to retire upon the completion of a deliberate succession process
and the appointment of a successor |
MINNEAPOLIS, Jan 8, 2024 – CVRx, Inc.
(NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company,
announced today certain preliminary unaudited fourth quarter and full year 2023 revenue results as well as its 2024 business outlook.
The Company also announced that President and Chief Executive Officer, Nadim Yared, has informed the Board of Directors of his plans
to retire following the selection and appointment of his successor.
Fourth Quarter 2023
Total revenue for the fourth
quarter of 2023 is expected to be in the range of approximately $11.2 million to $11.3 million, representing an increase of approximately
56% to 58% over fourth quarter 2022 revenue of $7.2 million. Total revenue generated in the fourth quarter of 2023 is expected to be comprised
of approximately $10.2 million in U.S. heart failure revenue, $1.0 million in European revenue and $0.1 million in U.S. legacy revenue.
Full Year 2023
Total revenue for full year
2023 is expected to be in the range of approximately $39.2 million to $39.3 million, representing an increase of approximately 74% to
75% over full year 2022 revenue of $22.5 million. Total revenue generated in 2023 is expected to be comprised of approximately $34.6 million
in U.S. heart failure revenue, $4.2 million in European revenue and $0.5 million in U.S. legacy revenue.
As of December 31, 2023,
the Company had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023. The number of sales territories
in the U.S. increased by three to a total of 38 during the three months ended December 31, 2023.
As of December 31, 2023, cash and cash equivalents
were $91 million.
“2023 was another fantastic
year for CVRx,” said Nadim Yared, President and Chief Executive Officer of CVRx. “We continued to drive the adoption and utilization
of Barostim, evidenced by the 97% increase in U.S. heart failure revenue. In addition, we announced several positive catalysts during
the year, including the recently announced expansion of Barostim labeling as well as CMS’ OPPS ruling to reassign Barostim to a
new APC code, which we believe will facilitate increased access to the therapy for Medicare patients with heart failure by offering facilities
sufficient reimbursement for the procedure.”
Business Outlook
For the full year of 2024,
the Company expects:
| · | Total revenue between $53.0 million and $57.0 million; |
| · | Gross margin between 83% and 84%; |
| · | Operating expenses between $86.0 million and $90.0 million. |
For the first quarter of 2024,
the Company expects to report total revenue between $11.0 million and $12.0 million.
CEO Retirement Plans and
Initiation of Search Process
The Company’s current
President and Chief Executive Officer, Yared, has informed the Board of Directors of his plans to retire. Both he and the Board are committed
to a planful and deliberate process to identify his successor, and Yared will remain in his current role until a new CEO is appointed.
The Board is currently conducting a search to identify a new CEO with the assistance of a leading executive search firm.
“As we look to 2024,
we are very excited about the prospects for the Company and the expanded penetration of Barostim. Based on the Company’s strong
position, excellent leadership team, consistent execution of our strategy over the last two years, and the opportunity that lies in front
of us, the Company is well-positioned to attract a high-caliber CEO who can continue to execute on our strategic plans and drive future
commercial growth,” Yared said. “My 17 years as CEO of CVRx have been an incredible experience and honor, and I look forward
to continuing to serve the Company and support the Board throughout this transition.”
“The Board of Directors
is grateful to Nadim for his extraordinary leadership and his commitment since his arrival at CVRx in 2006. He has worked tirelessly to
transform Barostim from an intriguing concept into a commercially successful FDA-approved therapy, and CVRx into a thriving public company,”
said Kirk Nielsen, lead independent director. “Nadim has contributed tremendously to the success of CVRx, and we look forward to
working closely with him to identify his successor and support a seamless transition.”
Upcoming Investor Conference Presentation
The Company will be participating in the 42nd Annual J.P. Morgan
Healthcare Conference, including a company presentation on Wednesday, January 10, 2024 at 3:45 pm Pacific Time. A live audio webcast
of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™
System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is
an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate
the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to
the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation
and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension
in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking
statements, including statements regarding our future financial performance (including our financial guidance regarding full year and
first quarter 2024 results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words.
The forward-looking statements in this press release are only predictions
and are based largely on our current expectations and projections about future events and financial trends that we believe may affect
our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history
of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single
product, Barostim; our ability to establish and maintain sales and marketing capabilities; our ability to demonstrate to physicians and
patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim;
our competitors’ success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise
more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers,
and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including
the outbreak of the novel strain of coronavirus, COVID-19; any failure of clinical studies for future indications to produce results necessary
to support regulatory clearance or approval in the U.S. or elsewhere; product liability claims; future lawsuits to protect or enforce
our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives
or recruit and hire new employees; and other important factors that could cause actual results, performance or achievements to differ
materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2022 and in “Part 2, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2023, as such factors may be updated from time to time in our other filings with the Securities
and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Preliminary Fourth Quarter/Full Year 2023 Results
This press release includes estimated financial results for the fourth
quarter and full year of 2023, which are preliminary, unaudited and represent the most recent current information available to Company
management. The Company’s actual results may differ from these estimated financial results, including due to the completion
of its financial closing procedures and final adjustments. The Company expects to issue full financial results for the fourth quarter
and full year 2023 in late January.
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443.213.0501
ir@cvrx.com
v3.23.4
Cover
|
Jan. 03, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 03, 2024
|
Entity File Number |
001-40545
|
Entity Registrant Name |
CVRx,
Inc.
|
Entity Central Index Key |
0001235912
|
Entity Tax Identification Number |
41-1983744
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
9201
West Broadway Avenue
|
Entity Address, Address Line Two |
Suite 650
|
Entity Address, City or Town |
Minneapolis
|
Entity Address, State or Province |
MN
|
Entity Address, Postal Zip Code |
55445
|
City Area Code |
763
|
Local Phone Number |
416-2840
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
stock, par value $0.01 per share
|
Trading Symbol |
CVRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni CVRx (NASDAQ:CVRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni CVRx (NASDAQ:CVRX)
Storico
Da Mag 2023 a Mag 2024